What is the appropriate workup for a patient with a positive hepatitis B core antibody (anti‑HBc)?

Workup for Positive Anti-HBc

A positive anti-HBc requires immediate testing of HBsAg, anti-HBs, and HBV DNA to determine if the patient has chronic infection, resolved infection, or isolated anti-HBc positivity. 1, 2, 3

Initial Serologic Interpretation

When anti-HBc is positive, the pattern of additional markers determines the clinical significance:

If HBsAg is Positive

• This indicates chronic HBV infection (if present >6 months) or acute infection (if <6 months with IgM anti-HBc positive) 1, 3
• Proceed immediately to full chronic hepatitis B workup (see below)

If HBsAg is Negative and Anti-HBs is Positive

• This represents resolved infection with natural immunity 2, 4
• No further workup needed in immunocompetent patients
• In immunocompromised patients planning chemotherapy or immunosuppression, check HBV DNA as occult infection can occur 5, 6, 7

If HBsAg is Negative and Anti-HBs is Negative (Isolated Anti-HBc)

This is the critical scenario requiring careful evaluation. Four possibilities exist 3:

1. Resolved infection with waning anti-HBs (most common in high-prevalence populations)
2. Occult hepatitis B (HBsAg undetectable but HBV DNA present)
3. False-positive anti-HBc
4. Window period of acute infection (rare)

Immediate next step: Check HBV DNA 1, 3

• If HBV DNA is detectable: Occult hepatitis B—manage as chronic infection 3, 7
• If HBV DNA is undetectable: Likely resolved infection or false-positive
  • Repeat HBsAg, anti-HBs, and anti-HBc in 3-6 months to confirm pattern 1, 3
  • Consider vaccination response testing: Give one dose of hepatitis B vaccine and check anti-HBs in 1 month 8, 9
    • Anamnestic response (anti-HBs >50 mIU/mL at 2 weeks or >10 mIU/mL at 4 weeks) confirms prior infection with immunity
    • No response suggests false-positive anti-HBc; complete vaccine series

Complete Workup for Confirmed Chronic HBV (HBsAg-Positive)

Once chronic infection is confirmed, perform comprehensive evaluation 1, 3:

Essential Laboratory Tests

• HBeAg and anti-HBe to determine disease phase
• Quantitative HBV DNA (defines viral replication level)
• Complete blood count with platelets
• Hepatic panel: AST, ALT, alkaline phosphatase, GGT, bilirubin, albumin
• Prothrombin time/INR
• Creatinine (baseline for potential antiviral therapy)

Coinfection Screening

• Anti-HCV (all patients)
• Anti-HDV if from endemic area or history of injection drug use 3
• Anti-HIV in high-risk patients 5, 3
• IgG anti-HAV in patients <50 years (vaccinate if negative) 1, 3

HCC Surveillance Baseline

• Abdominal ultrasound
• Alpha-fetoprotein (AFP) 3

Assessment of Liver Fibrosis

• Non-invasive fibrosis assessment (FibroScan, FIB-4, APRI) or
• Liver biopsy (optional but consider if age >40, borderline ALT elevation, or unclear treatment indication) 1, 5

Risk-Specific Considerations

For Immunocompromised or Cancer Patients

All patients with positive anti-HBc (regardless of HBsAg status) planning immunosuppression require 6, 7, 10:

• HBV DNA testing before starting therapy
• Risk stratification based on planned immunosuppression:
  • High risk (>10%): Anti-CD20 agents, stem cell transplant—requires antiviral prophylaxis
  • Moderate risk (1-10%): Most chemotherapy—prophylaxis recommended
  • Low risk (<1%): Corticosteroids <4 weeks—monitoring acceptable

For Transplant Recipients

• All anti-HBc positive renal transplant recipients need monitoring for HBsAg seroreversion 7
• HBsAg-positive transplant recipients require long-term antiviral therapy with high-barrier agents (entecavir or tenofovir) 7

Common Pitfalls to Avoid

1. Do not assume isolated anti-HBc is always benign—occult hepatitis B occurs in <10% but can reactivate with immunosuppression 2, 7

2. Do not rely on anti-HBc alone for screening—one study found it missed an acute infection when HBsAg was not checked 11

3. In patients receiving IVIG, anti-HBc can represent passive antibody transfer for up to 4 months—check pre-IVIG serology if possible 12

4. Serial monitoring is essential—single HBV DNA measurement may miss fluctuating viremia in HBeAg-negative disease 5, 13

5. Anti-HBs from vaccination does not include anti-HBc—presence of anti-HBc always indicates prior infection, not vaccination 1, 2, 3